Monash University
monash.eduTotal trials
92
Active
32
Phase 3
12
Total enrollment
365,380
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 27 of 27 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Cefazolin | — | — | — | — | — | 1 | |
| Water for | — | — | — | — | — | 1 | |
| Atorvastatin 40 Mg Oral | — | — | — | — | — | 1 | |
| Atorvastatin | — | — | — | — | — | 1 | |
| Liberal inspired oxygen | — | — | — | — | — | 1 | |
| Conservative inspired oxygen | — | — | — | — | — | 1 | |
| Intermediate inspired oxygen | — | — | — | — | — | 1 | |
| Immune Globulin Intravenous | — | — | — | — | — | 3 | |
| Trimethoprim / Sulfamethoxazole | — | — | — | — | — | 2 | |
| Melatonin 10 MG | — | — | — | — | — | 1 | |
| Intravenous immunoglobulin | — | — | — | — | — | 1 | |
| Amoxicillin clavulanic acid | — | — | — | — | — | 1 | |
| Trimethoprim Sulfamethoxazole | — | — | — | — | — | 1 | |
| Amoxycillin/clavulanic acid | — | — | — | — | — | 1 | |
| trimethoprim-sulfamethoxazole | — | — | — | — | — | 1 | |
| amoxycillin/clavulanic acid and ciprofloxacin | — | — | — | — | — | 1 | |
| Immunoglobulins | — | — | — | — | — | 1 | |
| Pfizer Bivalent COVID-19 Vaccine | — | — | — | — | — | 1 | |
| Moderna Bivalent mRNA vaccine | — | — | — | — | — | 1 | |
| lidocaine 2% and 10% | — | — | — | — | — | 1 | |
| STX-1150 | — | — | — | — | — | 1 | |
| Cladribine | — | — | — | — | — | 1 | |
| Dimethyl fumarate | — | — | — | — | — | 1 | |
| Fingolimod | — | — | — | — | — | 1 | |
| Teriflunomide | — | — | — | — | — | 1 | |
| Ozanimod | — | — | — | — | — | 1 | |
| Diroximel fumarate | — | — | — | — | — | 1 |
Next readouts
- 2025-11-19
- 2025-12
- 2026-06-30
- 2026-09
- 2027-03-31
- 2027-03-31
- 2027-03-31
- 2027-03-31
- 2027-04
- 2027-04-30
Top conditions
- Heart Failure6
- Myeloma4
- Leukemia4
- Non Hodgkin's Lymphoma3
- Cancer3
- Insulin Resistance3
- PreDiabetes2
- Dementia2
Frequently asked questions about Monash University
- How many clinical trials does Monash University have on ClinicalTrials.gov?
- Monash University is listed as the lead sponsor on 92 clinical trials in ClinicalTrials.gov, 32 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Monash University's trials are in Phase 3?
- 12 of Monash University's trials are in Phase 3, spread across 27 active drug programs.
- What therapeutic areas does Monash University focus on?
- Monash University's most-studied conditions on ClinicalTrials.gov are Heart Failure, Myeloma, Leukemia, Non Hodgkin's Lymphoma, Cancer.
- When are Monash University's next clinical trial readouts?
- Monash University has 10 upcoming primary-completion readouts tracked here; the soonest is “Relationship Between Oral DMT Burden and Adherence in MS”, expected around 2025-11-19.